VIA Pharmaceuticals Inc., of San Francisco, announced dosing of the first healthy volunteers in a Phase I trial of VIA-3196, the company's orally administered, liver-directed thyroid hormone beta receptor agonist for the treatment of high LDL cholesterol and other dyslipidemias including high triglycerides and elevated Lp (a).